PTAB grants IPR of Celgene patents after Kyle Bass challenge

The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board (PTAB) to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

IPR of pre-AIA patents isn’t unconstitutional, finds Fed Circuit

31 July 2019 In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review proceedings to a pre-American Invents Act patent isn’t unconstitutional.

Big Pharma

Celgene fends off Kyle Bass challenge

17 November 2015 Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.

Americas

Celgene reiterates stance on Kyle Bass IPRs

29 September 2015 Biopharmaceutical company Celgene has reiterated its stance on the inter partes review petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

PTAB grants IPR of Celgene patents after Kyle Bass challenge

More on this story

Editor's picks

Editor's picks

More features